Early rebleeding increases mortality of variecal bleeders on secondary prophylaxis with β-blockers and ligation

Dig Liver Dis. 2020 Sep;52(9):1017-1025. doi: 10.1016/j.dld.2020.06.005. Epub 2020 Jul 8.

Abstract

Background/aims: Despite secondary-prophylaxis with β-blockers and endoscopic-variceal-ligation rebleeding is frequent, particularly within the first-6-weeks. Early-rebleeding may have greater impact on death-risk than late rebleeding, which may affect therapy. We assessed whether the influence of rebleeding on long-term survival of patients on secondary-prophylaxis is greater in patients with early-rebleeding.

Methods: 369 patients with cirrhosis were consecutively included once recovered from first variceal-bleeding. The impact of rebleeding on survival was investigated according to whether it occurred within 6-weeks (early-rebleeding) or later (late-rebleeding).

Results: During 46-months of follow-up (IQR: 14-61), 45 patients (12%) had early-rebleeding, 74(20%) had late-rebleeding and 250(68%) had not rebleeding. Mortality risk was higher in early-rebleeding group vs. late-rebleeding (HR = 0.476, 95%CI = 0.318-0.712, p < 0.001) and was similar in late-rebleeding group vs. no-rebleeding (HR = 0.902, 95%CI = 0.749-1.086, p = 0.271). Adjusting for baseline risk-factors, early-rebleeding was independently associated with mortality-risk (HR = 1.58, 95%CI = 1.02-2.45; p = 0.04). Child-Pugh&MELD scores improved at 3rd-4th-week only in patients without early-rebleeding (p < 0.05). Presence of ascites or encephalopathy, MELD-score>12 and HVPG>20 mmHg identified patients at risk of early-rebleeding.

Conclusions: Patients with early-rebleeding have higher risk of death than patients without rebleeding and even than those rebleeding later. Our results suggest that patients at risk of early rebleeding might benefit from preemptive therapies such as early-TIPS.

Keywords: Complications of cirrhosis; Endoscopic variceal ligation; Portal hypertension; Variceal bleeding; β-blockers.

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use*
  • Adult
  • Aged
  • Combined Modality Therapy
  • Esophageal and Gastric Varices / etiology
  • Esophageal and Gastric Varices / mortality
  • Esophageal and Gastric Varices / physiopathology
  • Esophageal and Gastric Varices / therapy*
  • Female
  • Gastrointestinal Hemorrhage / etiology
  • Gastrointestinal Hemorrhage / mortality*
  • Gastrointestinal Hemorrhage / physiopathology
  • Gastrointestinal Hemorrhage / prevention & control*
  • Hepatic Encephalopathy / etiology
  • Humans
  • Ligation / methods
  • Liver Cirrhosis / complications*
  • Liver Cirrhosis / mortality
  • Male
  • Middle Aged
  • Portasystemic Shunt, Transjugular Intrahepatic / adverse effects
  • Portasystemic Shunt, Transjugular Intrahepatic / mortality
  • Prospective Studies
  • Recurrence
  • Secondary Prevention
  • Severity of Illness Index
  • Spain / epidemiology
  • Survival Analysis
  • Time Factors
  • Treatment Outcome

Substances

  • Adrenergic beta-Antagonists